Sorry CME is not currently available for this activity.

Update in IBD Therapies 2015

Author: Russell D. Cohen, MD
Professor of Medicine
Director, Inflammatory Bowel Disease Center
Co-Director, Advanced IBD Fellowship
Course Title: Update in IBD Therapies 2015
Activity Type: Enduring Material, video with PPT, eLearning
Activity Length: 22 min
Test Time: 5 min

Short Description: Treatment options in inflammatory bowel disease range from mesalamine and budesonide for mild to moderate disease to immuomodulators for patients with refractory disease to the biologic agents for moderate to severe disease. Recent breakthroughs include agents currently FDA-approved for Crohn’s disease or ulcerative colitis as well as those indicated for other inflammatory conditions such as rheumatoid arthritis and psoriasis. Future therapies include novel monoclonal antibodies as well as orally available small molecules. 

This presentation was originally recorded at the Best of the Annual Conferences in Digestive Diseases on June 13, 2015 in Rosemont, IL.

Disclosure: As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

The University of Chicago Pritzker School of Medicine, requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Russell D. Cohen, MD has served on the Speaker’s Bureau for AbbVie, Entera Health, Salix Pharmaceuticals, and Shire PLC. He has served in consulting, advisory, data safety monitoring and scientific advisory board capacity with AbbVie Laboratories, Celgene, Entera Health, Hospira, Janssen (Johnson & Johnson/Centocor), Prometheus Laboratories, Salix Pharmaceuticals, Sandoz Biopharmaceuticals, Shire pLC, Takeda, and UCB Pharma.

The staff of the University of Chicago Center for Continuing Medical Education have no financial relationships to disclose. 

CME Information:

Learning Objectives: After completing this activity, the participant will demonstrate the ability to:

  1. Identify currently available FDA-approved therapies for the treatment of Crohn’s disease and ulcerative colitis;
  2. Identify currently available FDA-approved therapies for other indications that have clinical data in the treatment of IBD;
  3. Identify novel therapeutic mechanisms in development as potential therapies in IBD.

Primary Audience: Gastroenterologist, Surgeons, Nurses, Nurse Practitioners, Physician Assistants, and Residents/Fellows.

Accreditation and Credit Designation: The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.

Disclaimer: The information presented in this activity is for continuing medical education purposes only.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the University of Chicago Pritzker School of Medicine, the University of Chicago Medicine, or the Department/Section.

Instructions for Participation and Credit: This online educational activity (enduring material) is designed to be completed within the time designated. To successfully earn credit, participants must complete the activity online during the valid credit period. To receive AMA PRA Category 1 Credit™ , the participant must complete the activity evaluation and correctly answer 5 out of 6 questions (83% pass rate) on the post-test. The test can be accessed by clicking on the appropriate certificate link at the top of this page. Upon successful completion, the participant may save or print their certificate (pdf).

Certificate of Credit     

Physicians: Only physician participants (MD, DO, or equivalent international medical degree) are eligible to receive AMA PRA Category 1 Credit™.

Certificate of Participation 

Non-Physicians will receive a certificate indicating participation in this AMA PRA Category 1 Credit™ approved activity. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.

For questions about CME credit, please contact the Center for CME at The University of Chicago at cme@bsd.uchicago.edu 

Commercial Support: This CME certified activity has not received any support or funding from commercial interests.  This includes, but is not limited to, pharmaceutical companies and medical device manufacturers.

Selected Publications:

View a partial list of Dr. Cohen's publications through the National Library of Medicine's PubMed online database.

Release Date: 10/01/2015     Expiration Date: 10/01/2016

Presenter

Russell D. Cohen, MD

Russell D. Cohen, MD Professor of Medicine
View Full Profile